AMGEN INC — Director's Dealing 2022

Mar 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2022-03-01

Reporting Person: Khosla Rachna (SVP, Business Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-01	Common Stock	A	923	—	Acquired	7139	Direct

Footnotes

F1: These shares include the following RSUs granted under the Company's equity plans: 67 RSUs which will vest on 4/27/2022; 554 RSUs which will vest on 7/31/2022; 280 RSUs which vest in installments of 138 on 5/3/2022 and 142 on 5/3/2023; 300 RSUs which will vest in two installments of 99 on 5/5/2022 and 5/5/2023 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2: These shares include 134 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.